[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_NewBusinessRelationAbstract|
New Business Relation
oda_UpdateAnnouncementFlag|
Update Notification Flag
Evet (Yes)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
08.09.2022
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
Nature Of The Other Party With Which New Business Relation Will Start
Tedarikçi (Supplier)
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
Name Surname Or Company Title Of Customer Or Supplier
Sanovel İlaç Sanayi ve Ticaret A.Ş.
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
If Exists Share Of Customer Or Supplier In Net Sales Or Cost Of Goods Sold On Latest Disclosed Profit Or Loss And Other Comprehensive Income Statement Of Company
-
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
If Exists Share Of Customer Or Supplier In Trade Receivables Or Debts On Latest Disclosed Statement of Financial Position Of Company
-
oda_ExpectedStartingDateOfNewBusinessRelation|
Expected Starting Date O fNew Business Relation
25/10/2023
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
If Exist Significant Provisions Of The Contract
Detailed below
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
Impact Of New Business Relation On Company Activities
Positive impact is expected
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

-Unofficial Translation-

According to the Agreement signed between Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("Gen") and Sanovel İlaç Sanayi ve Ticaret A.Ş. ("Sanovel") on 16.11.2021 ( https://www.kap.org.tr/en/Bildirim/978109 ) and revised on 08.09.2022 with additional protocol ( https://www.kap.org.tr/en/Bildirim/1061385 ) sales and distribution of some products which produced by Sanovel on Azerbaijan and Uzbekistan markets was disclosed.

On 25.10.2023 a new additional protocol signed between GEN and Sanovel. With this additional protocol the products which our company will sell and distribute re-determined and it has been decided that some Sanovel products will be distributed by our Company in the Georgian market in addition to the previous regions.

Sanovel Products which will be sell and distributed by our Company in Azerbaijan: Ticagrelor active substanced products, Nebivalol active substanced products, Levetiracetam active substanced products, Dapagliflozin active substanced products and Sacubitril+Valsartan active substanced products.

Sanovel Products which will be sell and distributed by our Company in Uzbekistan: Nebivalol active substanced products, Dapagliflozin active substanced products and Sacubitril+Valsartan active substanced products.

Sanovel Products which will be sell and distributed by our Company in Georgia: Dapagliflozin active substanced products and Sacubitril+Valsartan active substanced products.

Contribution of the sales and distribution of these products within the framework of this agreement to our Company's gross sales, is expected as 198.000 boxes and approximately USD 1.920.370 (approximately TL 53.950.000 with the current exchange rates) for 2023 (2023 sales made until today are included), 292.300 boxes and approximately USD 2.972.042 (approximately TL 83.500.000 with the current exchange rates) for 2024 and 410.100 boxes and approximately USD 4.060.954 (approximately TL 114.100.000 with the current exchange rates) for 2025